A few months ago, a new patient walked into my clinic carrying a folder nearly two inches thick. She had undergone years of physical therapy, chiropractic care, epidural steroid injections, anti-inflammatory medications, opioid therapy, and consultations with multiple specialists. Before sitting down, she asked a question I now hear almost weekly: “Doctor, what about stem cells? I’ve heard they can regenerate my spine.”

It is a reasonable question and one that reflects the growing public interest in regenerative medicine. Patients are increasingly seeking alternatives to surgery, chronic opioid therapy, and repeated corticosteroid injections. They are looking for treatments that address the underlying cause of pain rather than simply masking symptoms.

As an interventional pain physician, I share that goal. I offer regenerative procedures in appropriately selected patients because biologic therapies have an important role in modern pain management. However, our specialty also has an obligation to separate scientific evidence from marketing hype. The future of regenerative medicine will not be determined by enthusiasm alone. It will be determined by rigorous science, transparent patient counseling, and responsible clinical practice.

A paradigm shift in pain medicine

For decades, chronic pain treatment has focused primarily on symptom reduction. Medications decrease pain perception, steroid injections suppress inflammation, and surgery corrects structural pathology. While these approaches remain valuable, regenerative medicine introduces a different concept: supporting the body’s intrinsic healing mechanisms.

Platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and other orthobiologic therapies aim to deliver growth factors, cytokines, and cellular components that may promote tissue repair and modulate inflammatory pathways. Unlike corticosteroids, which primarily inhibit inflammation, these biologic therapies seek to create an environment conducive to healing. This distinction explains why regenerative medicine has attracted significant interest among pain physicians, orthopedic surgeons, sports medicine specialists, and patients alike.

PRP: the strongest evidence among orthobiologics

Among regenerative therapies, platelet-rich plasma currently has the most robust clinical evidence. PRP is prepared from the patient’s own blood and contains a concentrated population of platelets that release bioactive proteins, including platelet-derived growth factor, transforming growth factor-beta, vascular endothelial growth factor, and insulin-like growth factor.

Numerous randomized controlled trials and systematic reviews suggest that PRP may improve pain and function in selected patients with knee osteoarthritis, lateral epicondylitis, plantar fasciitis, and several chronic tendinopathies. Meta-analyses have reported sustained improvements compared with corticosteroid injections or hyaluronic acid in some patient populations. For example, a meta-analysis of randomized trials found that patients treated with PRP for knee osteoarthritis experienced significantly greater improvements in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores than those receiving hyaluronic acid, with some evidence favoring leukocyte-poor preparations. A separate meta-analysis similarly reported that intra-articular PRP provided superior pain relief and functional improvement compared with hyaluronic acid at 12 months.

Yet even PRP illustrates an important challenge within regenerative medicine: Not all PRP preparations are the same. Differences in platelet concentration, leukocyte content, centrifugation protocols, activation techniques, injection methods, and post-procedure rehabilitation make direct comparison between studies difficult. Two investigations evaluating “PRP” may actually be studying biologic products with substantially different characteristics. This lack of standardization remains one of the greatest barriers to translating promising research into universally accepted clinical guidelines.

Bone marrow concentrate and cell-based therapies

Bone marrow aspirate concentrate represents another promising area of investigation. Rather than consisting solely of stem cells, BMAC contains a heterogeneous mixture of mesenchymal stromal cells, hematopoietic cells, cytokines, platelets, and other biologically active components.

Preliminary clinical studies and registry data suggest that BMAC may improve pain and function in carefully selected patients with knee osteoarthritis and certain degenerative musculoskeletal disorders. Some work has linked higher progenitor cell concentrations in the injectate to better patient-reported outcomes. However, the current literature is characterized by relatively small sample sizes, heterogeneous methodologies, and limited long-term follow-up. As clinicians, we should acknowledge both the promise and the limitations of these data. Encouraging early outcomes are not synonymous with definitive evidence.

The stem cell conversation we need to have

Perhaps no term has been more misunderstood than “stem cells.” Patients frequently arrive expecting a single injection capable of regenerating cartilage, reversing spinal degeneration, or eliminating chronic pain. These expectations are often shaped by aggressive direct-to-consumer advertising rather than peer-reviewed science.

The U.S. Food and Drug Administration has repeatedly cautioned that most stem cell products marketed for orthopedic and pain conditions have not received FDA approval and should not be promoted as proven therapies. Currently, the only stem cell products approved by the FDA in the United States are certain blood-forming (hematopoietic) stem cells derived from umbilical cord blood, and these are approved only for specific blood disorders, not for orthopedic or chronic pain indications. Exosome products and many other regenerative offerings also lack FDA approval for these uses.

Responsible physicians have an ethical obligation to communicate this distinction clearly. In my practice, regenerative medicine is never presented as a miracle treatment. It is presented as one component of a comprehensive treatment plan that includes rehabilitation, exercise, weight optimization when appropriate, behavioral health, image-guided interventions, and conventional medical management. Patients appreciate honesty. They deserve realistic expectations, not unrealistic promises.

Innovation must be matched by evidence

One of the most encouraging developments in recent years has been the increasing involvement of professional societies in evaluating regenerative medicine.

The American Society of Interventional Pain Physicians (ASIPP) has published evidence-based guidelines on the responsible, safe, and effective use of biologics in the management of low back pain. These guidelines recognize the promise of biologic therapies while emphasizing that the quality of evidence varies substantially by indication, with Level III evidence for certain intradiscal applications of PRP and mesenchymal stem cells and lower levels for other spinal targets. More recent ASIPP updates continue to stress careful patient selection, adherence to FDA regulations, and the need for ongoing research.

Likewise, the American Society of Pain and Neuroscience (ASPN) has developed evidence-based clinical practice guidelines on regenerative medicine for chronic pain. These consensus recommendations address injectable biologics (including PRP, BMAC, and others), mechanisms, safety, comparative efficacy, peri-procedural practices, regulatory considerations, and complications. They conclude that, in well-selected patients with certain chronic pain indications, injectable biologics may provide superior analgesia, function, or quality of life compared with conventional medical management or placebo. They also call for higher-quality trials, standardized preparation protocols, and better reporting standards.

These organizations are not discouraging innovation. They are encouraging responsible innovation. That distinction matters. Our specialty has experienced tremendous advances because physicians were willing to investigate new techniques while simultaneously demanding scientific validation. Regenerative medicine deserves the same disciplined approach.

The American Academy of Orthopaedic Surgeons has also evaluated the evidence for PRP in knee osteoarthritis, noting that it may reduce pain and improve function (limited strength of recommendation) while highlighting inconsistencies, cost concerns, and the need for better research.

The insurance paradox

One of the greatest frustrations shared by physicians and patients is reimbursement. Despite increasing evidence supporting PRP for selected musculoskeletal conditions, many commercial insurers continue to classify these procedures as investigational. Coverage for BMAC and other orthobiologic therapies is even more limited.

Consequently, patients often pay thousands of dollars out of pocket for treatments that may ultimately reduce disability, postpone surgery, and decrease reliance on opioid medications. This disconnect between emerging evidence and insurance policy highlights the need for larger multicenter randomized trials capable of informing future coverage decisions and for clearer communication of both benefits and limitations to payers and patients alike.

Looking ahead

Regenerative medicine should not divide physicians into believers and skeptics. Instead, it should unite us around a common objective: providing patients with safe, evidence-based therapies that improve function and quality of life.

The next decade will likely determine where biologics ultimately fit within interventional pain management. Advances in biologic characterization, standardized preparation protocols, biomarker-guided patient selection, and high-quality randomized trials will shape future clinical guidelines.

As physicians, our responsibility is not merely to adopt new technologies. It is to critically evaluate them, contribute to the scientific literature, and ensure that every recommendation we make is grounded in both clinical experience and the best available evidence.

Innovation without evidence is marketing. Evidence without innovation limits progress. The future of pain management requires both.

Kayvan Haddadan is a physiatrist and pain management physician, and president and medical director of Advanced Pain Diagnostic & Solutions, a multidisciplinary pain management practice in California that he founded in 2012. A physician and surgeon licensed by the Medical Board of California, he is double board-certified in pain medicine and physical medicine and rehabilitation. He is also certified in controlled substance registration through the DEA and serves as a qualified medical examiner through California’s Department of Industrial Relations Division of Workers’ Compensation.

Dr. Haddadan earned his Bachelor of Science degree from the College of Alborz in Tehran, Iran, and his medical degree from Shahid Beheshti University of Medical Sciences. He later received his Educational Commission for Foreign Medical Graduates certification in Philadelphia, completed an internship in medical surgery at Loyola University Medical Center’s Stritch School of Medicine in Illinois, and finished his residency in physical medicine and rehabilitation at the same institution. He completed his fellowship in pain medicine at California Pacific Medical Center’s Pacific Pain Treatment Center and also trained in medical acupuncture for physicians at the University of California, Los Angeles David Geffen School of Medicine.

Dr. Haddadan has contributed to 29 research publications across multiple specialties, including pain management, cardiology, pulmonology, endocrinology, gastroenterology, and infectious disease. His work has examined topics such as hyperlipidemia in high cardiovascular risk patients, hyperuricemia and gout management, type 2 diabetes and hypertension, chronic obstructive pulmonary disease and asthma therapies, influenza treatment, irritable bowel syndrome, and opioid related complications in chronic pain care. His research has also included clinical outcome studies in spinal cord stimulation and award-winning presentations on neuropathic pain management and neuromuscular disorders.